Aurobindo Pharma officials will participate in the Investec US Pharma and Healthcare Bus Tour 7.0, a group investor meeting scheduled for June 4, 2026, in New Jersey, USA. The meeting is part of the company's ongoing investor engagement activities and will provide an update on its operations to the investment community. The interaction is scheduled to take place between 13:00 and 15:00 EDT.

The company clarified that no unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. The schedule of the meeting remains subject to change due to exigencies on the part of the investors or the company.

Meeting Details

The disclosure was submitted to the National Stock Exchange of India Limited and BSE Limited on May 27, 2026. aurobindo pharma is a Hyderabad-based pharmaceutical manufacturer.

Aurobindo Pharma Limited announced that the United States Food and Drug Administration (US FDA) has classified Unit-I of its wholly owned subsidiary, Eugia Pharma Specialities Limited, as “Official Action Indicated” (OAI). The regulatory action follows an inspection of the formulation manufacturing facility situated at Kolthur Village, Shameerpet Mandal, Ranga Reddy, Telangana.

The inspection was conducted by the US FDA from February 16 to February 27, 2026. During this period, the authority identified four observations at the facility. The company received the formal communication regarding the OAI classification on May 23, 2026.

Details of the Regulatory Action

The classification of OAI signifies that regulatory officials recommend official administrative or regulatory action. This status is assigned when the inspection conditions warrant such measures. Despite the classification, the company has affirmed its commitment to maintaining the highest quality manufacturing standards across its global facilities.

Impact Assessment

In its disclosure to the stock exchanges, Aurobindo Pharma clarified that there is no impact on the company’s financials or operations as a result of this action. The company stated that it would inform the exchanges if any further information regarding the matter arises.

Inspection Summary